25th week of 2010 patent applcation highlights part 49 |
Patent application number | Title | Published |
20100158894 | PREVENTIVE OR REMEDY FOR ER-NEGATIVE AND HER2-NEGATIVE BREAST CANCER AND METHOD OF SCREENING THE SAME - The present invention provides (1) an agent for the prevention or treatment of an estrogen receptor-negative and HER2-negative breast cancer comprising an Akt inhibitor, (2) an agent for the prevention or treatment of an estrogen receptor-negative, progesterone receptor-negative and HER2-negative breast cancer comprising an Akt inhibitor, (3) a method of screening an agent for the prevention or treatment of a breast cancer which is negative for hormone receptors such as an estrogen receptor, a progesterone receptor, etc. and is negative for HER2, which comprises using an Akt inhibitory activity as an indicator; and so on. | 2010-06-24 |
20100158895 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 2010-06-24 |
20100158896 | ANTIBODY THAT SPECIFICALLY BINDS HYALURONAN SYNTHASE - Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis. | 2010-06-24 |
20100158897 | PAI-1 MODULATORS FOR THE TREATMENT OF OCULAR DISORDERS - The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 activity. In a preferred embodiment, the agent that modulates PAI-1 expression and/or activity is cilostazol or an analog or metabolite of cilostazol. | 2010-06-24 |
20100158898 | METHODS OF TREATING IgE-MEDIATED DISORDERS COMPRISING THE ADMINISTRATION OF HIGH CONCENTRATION ANTI-IgE ANTIBODY FORMULATIONS - The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. | 2010-06-24 |
20100158899 | PROTEIN FORMULATION - A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein. | 2010-06-24 |
20100158900 | ANTI-MARINOBUFAGENIN ANTIBODIES AND METHODS FOR THEIR USE - Described herein are deposited hybridoma cell lines and the monoclonal antibodies produced by these hybridomas, and antigen binding fragments thereof. These monoclonal antibodies and antigen binding fragments specifically bind marinobufagenin. The disclosure also encompasses the use of these monoclonal antibodies or antigen binding fragments in a method for detecting the presence of marinobufagenin in a biological sample. Also provided are methods for the use of these monoclonal antibodies or antigen binding fragments as prophylactic, therapeutic, and diagnostic agents for the detection, inhibition and treatment of a cardiovascular disease, for example, essential hypertension, hypertension associated with preeclampsia, eclampsia, or renal failure, or myocardial fibrosis in a subject. | 2010-06-24 |
20100158901 | ANTI-CD19 ANTIBODY THERAPY FOR AUTOIMMUNE DISEASE - The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 2010-06-24 |
20100158902 | MONOCLONAL ANTIBODIES AGAINST STROMAL DERIVED FACTOR-1 (SDF-1) - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to SDF-1 with high affinity. Nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells and methods for expressing the SDF-1 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the SDF-1 antibodies are also provided. Methods for detecting SDF-1, as well as methods for treating various B cell malignancies, including breast cancer, multiple myeloma and non-Hodgkin's lymphoma, and autoimmune disorders are disclosed. | 2010-06-24 |
20100158903 | METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS - The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use. | 2010-06-24 |
20100158904 | TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES - The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin. | 2010-06-24 |
20100158905 | COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST - Combination therapy is disclosed herein for the treatment an arthritic condition (e.g. rheumatoid arthritis, osteoarthritis or psoriatic arthritis). The therapies disclosed herein comprise administering tranilast or an analogous compound in combination with a pharmaceutical agent, such as a non-steroidal anti-inflammatory drug, a disease-modifying drug, a COX-2 inhibitor, an antibiotic, an analgesic or combination thereof. | 2010-06-24 |
20100158906 | METHODS FOR AUGMENTING AN IMMUNE RESPONSE USING ANTI-CD40 ANTIBODIES - The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand. | 2010-06-24 |
20100158907 | CONNECTIVE TISSUE GROWTH FACTOR FRAGMENTS AND METHODS AND USES THEREOF - The present invention is directed to CTGF fragments comprising at least exon 4 or exon 5 of CTGF and having mitogenic activity. The present invention is further directed to methods using said CTGF fragments to identify compositions which modulate the mitogenic activity of said CTGF fragments and to the compositions so identified. | 2010-06-24 |
20100158908 | Stable Polypeptide Formulations - The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a therapeutic polypeptide with a concentration of divalent cation between about 5-150 150 mM in a buffer having a pH less than 6.0 and an excipient comprising a sugar or polyol. | 2010-06-24 |
20100158909 | Variant Target Binding Agents and Uses Thereof - The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells. | 2010-06-24 |
20100158910 | TREATMENT OF RENAL CELL CARCINOMA WITH ANTI-CD70 ANTIBODY-DRUG CONJUGATES - Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing a cancer, comprising administering to a subject the disclosed pharmaceutical compositions. | 2010-06-24 |
20100158911 | Compositions and Methods of Treating Disease with FGFR Fusion Proteins - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 2010-06-24 |
20100158912 | MONITORING AND INHIBITING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BY MODULATING HMGB1 DEPENDENT TRIGGERING OF HIV-1 REPLICATION AND PERSISTENCE - Compositions and methods for modulating human immunodeficiency virus (HIV) infection involving substances that inhibit the ability of high mobility box 1 (HMGB1) protein to interact with natural killer (NK) cells. Therapeutic compositions comprising antibodies and drugs, such as glycyrrhizin, which bind to HMGB1. Methods of detecting or monitoring HIV infection involving detection or quantitation of HMGB1 or antibodies specific for HMGB1 in a biological sample. | 2010-06-24 |
20100158913 | Antibody Molecules Having Specificity for Human IL-1B - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1β, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 2010-06-24 |
20100158914 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 2010-06-24 |
20100158915 | Method for Diagnosis and Treatment of Pancreatic Cancer - A technique for diagnosing pancreatic cancer includes measuring either level of IgE or cell surface bound cd23 (sCD23) in the patient, comparing the IgE or sCD23 level with that of patient known to have pancreatic cancer and with a level of IgE or sCD23 from a control patient known to not have pancreatic cancer, and identifying the level of IgE or sCD23 in the patient as analogous to either the control patient known to have pancreatic cancer or the control patient known to not have pancreatic cancer A technique for mediating ADCC against pancreatic cancer cells by administering a therapeutically effective amount of IgE to a source containing one or more pancreatic cancer cells. | 2010-06-24 |
20100158916 | DIAGNOSTIC BIOMOLECULE(S) - The present invention relates to methods for the identification and/or quantification of biomolecule(s). There is also provided a novel method of identifying and/or quantitating biomolecule(s) in a proliferative cell disorder by providing at least one cyst fluid sample and determining the expression of haptoglobin protein, derivative, mutant and/or fragment thereof. | 2010-06-24 |
20100158917 | Methods for diagnosing cancer and decreasing metastasis by cancer cells - The invention provides a protein that is a tumor marker protein. This protein can be used to prepare antibodies that bind to the tumor marker protein. These antibodies can be used to reduce, or eliminate metastasis by cancer cells that produce the tumor marker protein. In addition, the invention provides methods that can be used to diagnose cancer, and metastasis by cancer cells. | 2010-06-24 |
20100158918 | Polypeptides and polynucleotides encoding same - The invention provides polypeptides, designated herein as SECP polypeptides, as well as polynucleotides encoding SECP polypeptides, and antibodies that immunospecifically-bind to SECP polypeptide or polynucleotide, or derivatives, variants, mutants, or fragments thereof. The invention additionally provides methods in which the SECP polypeptide, polynucleotide, and antibody are used in the detection, prevention, and treatment of a broad range of pathological states. | 2010-06-24 |
20100158919 | Pharmaceutical Composition - The present invention relates to an anti-IGF-1R human monoclonal antibody formulation, a process for the preparation of said formulation and uses thereof | 2010-06-24 |
20100158920 | FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR - This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs. | 2010-06-24 |
20100158921 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. | 2010-06-24 |
20100158922 | Anti-Interferon Gamma Antibodies and Methods of Use Thereof - The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and/or modulating the biological activities of IFNγ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder. | 2010-06-24 |
20100158923 | REDUCING POLYGLUTAMINE-BASED AGGREGATION - The disclosure features, inter alia, methods for treating or preventing neurodegenerative disorders and disorders that caused at least in part by polyglutamine aggregation. The method can include reducing activity of the IGF-1/GH axis in a subject. One exemplary neurodegenerative disorder that is also caused at least in part by polyglutamine aggregation is Huntington's disease. | 2010-06-24 |
20100158924 | Expression of the cysteine protease legumain in vascular and inflammatory diseases - The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists and antagonists, in modulating legumain and/or ZB-1 activity, expression, and/or secretion in a cell or cell population, e.g., monocytes, macrophages, foam cells, vascular endothelial cells, kidney proximal tubule cells, arterial endothelial cells, sites of inflammatory cell invasion into a vessel intima, and neointimal lesional areas of an artery. The invention also provides legumain and ZB-1 antagonists, e.g., antagonistic small molecules, antibodies and antibody fragments to legumain and ZB-1, legumain and ZB-1 inhibitory polypeptides, and legumain and ZB-1 inhibitory polynucleotides. The present invention is also directed to novel methods for diagnosing, prognosing, monitoring, treating, ameliorating and/or preventing vascular disorders/diseases and inflammatory disorders/diseases. | 2010-06-24 |
20100158925 | Lyophilized formulations of anti-egfr antibodies - In one embodiment, the present invention provides a stable lyophilized formulation comprising an anti-EGFR antibody, preferably cetuximab; lactobionic acid; and a buffer, preferably histidine. In one preferred embodiment, the present invention provides a stable lyophilized formulation comprising about 50 mg/mL to about 140 mg/mL of ERBITUX?, about 0.125% lactobionic acid, about 25 mM histidine buffer at a pH of about 6.0, about 0.005% Tween 80, and about 1.875% glycine. | 2010-06-24 |
20100158926 | ANTIBODIES TO ERBB2 - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically hind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 2010-06-24 |
20100158927 | ANTIBODIES, METHODS AND KITS FOR DIAGNOSING AND TREATING MELANOMA - A method of diagnosing melanoma and antibodies capable of same are disclosed. The method comprises contacting a cell of the subject with an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a tyrosinase peptide, wherein the antibody does not bind the MHC-I in the absence of the complexed peptide, and wherein the antibody does not bind the peptide in an absence of the MHC, under conditions which allow immunocomplex formation, wherein a presence of the immunocomplex or level thereof is indicative of the melanoma. Methods for treating melanoma and antibodies capable of same are also disclosed. Pharmaceutical compositions comprising antibodies are also disclosed. | 2010-06-24 |
20100158928 | IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS - The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety. | 2010-06-24 |
20100158929 | NOVEL FORMULATIONS OF TUMOUR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR CLASS II MOLECULES FOR VACCINE - The present invention relates to novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumour immune responses. | 2010-06-24 |
20100158930 | HPV ANTIGEN FUSION PROTEIN VACCINE COMPOSITIONS AND USES THEREOF - The present invention provides a fusion protein comprising an immunostimulatory polypeptide and a mutant E7 protein of a human papilloma virus. The present invention also provides a gene encoding the fusion protein, expression vectors containing the gene, a pharmaceutical composition comprising the fusion protein, a method for treating or preventing a human papilloma virus related disease by using the fusion protein and uses of the fusion protein in the preparation of a medicament for the treatment or prevention of the human papilloma virus related disease. | 2010-06-24 |
20100158931 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 2010-06-24 |
20100158932 | Antibodies directed against prothrombin fragment F1+2, the preparation and use thereof - The invention relates to antibodies directed against F | 2010-06-24 |
20100158933 | IGE CH3 PEPTIDE VACCINE - The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 2010-06-24 |
20100158934 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 161P2F10B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization. | 2010-06-24 |
20100158935 | MUTANT FORMS OF STREPTOLYSIN O - Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against | 2010-06-24 |
20100158936 | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS - The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjugate that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections. | 2010-06-24 |
20100158937 | METHODS FOR CONJUGATION OF OLIGOSACCHARIDES OR POLYSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME LINKAGES VIA 3-DEOXY-D-MANNO-OCTULSONIC ACID - Methods for preparing an oligosaccharide-protein carrier immunogenic conjugate or a polysaccharide-protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier. | 2010-06-24 |
20100158938 | Tetravalent Dengue Vaccines - The invention provides tetravalent Dengue vaccines, and methods of using these vaccines to prevent or to treat Dengue infection. | 2010-06-24 |
20100158939 | VACCINE AGAINST PANDEMIC STRAINS OF INFLUENZA VIRUSES - The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided. | 2010-06-24 |
20100158940 | MANUFACTURE OF BOOSTER VACCINES HAVING REDUCED ANTIGEN DOSES - A process for manufacturing a vaccine, wherein the vaccine comprises diphtheria toxoid and tetanus toxoid and, and wherein the process comprises steps of combining (i) a first bulk comprising diphtheria toxoid and tetanus toxoid with (ii) a second bulk comprising tetanus toxoid but no diphtheria toxoid. This arrangement facilitates convenient manufacture of both pediatric and adolescent vaccines from the same bulks: the first bulk can have a diphtheriartetanus ratio that is suitable for pediatric vaccines, and the second bulk can be used to reduce the relative amount of diphtheria toxoid, as found in the adolescent vaccines. | 2010-06-24 |
20100158941 | Compositions and Methods for Treating Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2010-06-24 |
20100158942 | ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS - The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. | 2010-06-24 |
20100158943 | ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH INFLUENZA VACCINES - Patients receive a mucosal influenza vaccine and then receive a parenteral influenza vaccine, in that order, typically during different visits to a vaccination center. | 2010-06-24 |
20100158944 | Method for influenza virus protection - A process for the purification of influenza virus or derivative thereof comprising the steps of:
| 2010-06-24 |
20100158945 | ATTENUATED POLIO VIRUSES - The invention provides an attenuated poliovirus which does not have a base pair mismatch in stem (a) or (b) of domain V of the 5′ non-coding region of its genome, wherein at least seven of the base pairs in stems (a) and (b) are U-A or A-U base pairs. | 2010-06-24 |
20100158946 | Secretory IgA and IgG Antibody Inducer - A nasal vaccine is provided which induces the production of secretory IgA and IgG antibodies specific for flaviviruses, including hantaviruses. Furthermore, a method for providing protection against infection with flaviviruses by induces of the secretory IgA and IgG antibodies is also provided. The nasal vaccine includes an inactivated antigen of a flavivirus and poly(I:C) or a ceramified powder of surf clam shells as an adjuvant. The vaccine effectively induces secretion of IgA antibodies in the nasal mucosa and serum IgG antibody responses. Also provided is a method for inducing flavivirus-specific IgA and IgG antibodies, including administering an inactivated antigen of a flavivirus and poly(I:C) or a ceramified powder of surf clam shells as an adjuvant to the mucosa of a respiratory tract. | 2010-06-24 |
20100158947 | PERMISSIVE CELLS AND USES THEREOF - The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Methods of using said cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of said virus for the purpose of vaccine production or diagnosis, are also provide by the present invention. | 2010-06-24 |
20100158948 | ADAPTIVE MUTATIONS ALLOW ESTABLISHMENT OF JFH1-BASED CELL CULTURE SYSTEMS FOR HEPATITIS C VIRUS GENOTYPE 4A - The present inventors developed three 4a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 4a reference strain ED43. The 4a/2a junction in NS2 was placed after the first transmembrane domain (a), in the cytoplasmic part (β) or at the NS2/NS3 cleavage site (y). Following transfection of Huh7.5 cells with RNA transcripts, infectious viruses were produced in the ED43/JFH1-β and -y cultures only. Compared to the 2a control virus, production of infectious viruses was significantly delayed. However, in subsequent passages efficient spread of infection and high HCV RNA titers were obtained. Infectivity titers were approximately 10-fold lower than for the 2a control virus. Sequence analysis of recovered 4a/2a recombinants from 3 serial passages and subsequent reverse genetic studies revealed a vital dependence on a mutation in the NS2 4a part. ED43/JFH1-γ further depended on a second NS2 mutation. Infectivity of the 4a/2a viruses was CD81 dependent. Conclusion: The developed 4a/2a viruses provide a robust in vitro tool for research in HCV genotype 4, including vaccine studies and functional analyses of an increasingly important genotype in the Middle East and Europe. | 2010-06-24 |
20100158949 | Compositions and Methods for Vaccinating Against HSV-2 - This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method. | 2010-06-24 |
20100158950 | USE OF TETANUS TOXIN TO AMPLIFY INADEQUATE VOLUNTARY MUSCLE CONTRACTION OR TO IMPROVE MUSCLE TONE IN AN ANIMAL ACTIVELY VACCINATED AGAINST THE TOXIN AND A REGIMEN FOR TREATMENT - A method of improving muscle movement, contraction and/or tone in an animal is provided. The method is carried out by administering tetanus toxin to the muscle of an animal has already been vaccinated against tetanus toxin. The toxin is administered in an amount sufficient to improve muscle movement, contraction and/or tone. The method may be used to treat patients with impaired muscle function, e.g due to compromise of the central nervous system (for example, due to stroke or spinal cord injury) or due to muscle atrophy (for example, due to immobilization after an injury). A regimen for dosage escalation of tetanus toxin is also provided. | 2010-06-24 |
20100158951 | Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition - The disclosure provides a method of preparing an immunologically-active adjuvant-bound freeze dried vaccine composition. A specific embodiment provides a stable vaccine composition comprising an aluminum-salt adjuvant, a recombinant | 2010-06-24 |
20100158952 | MICROORGANISMS OR FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES - The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the same and to a method of prevention and treatment of core-1 positive disorders using the same. The invention relates to microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates. | 2010-06-24 |
20100158953 | METHOD FOR CONTROLLING STREPTOCOCCUS PNEUMONIAE SEROTYPE 19A POLYSACCHARIDE MOLECULAR WEIGHT - The present invention provides improved methods for producing a solution containing high molecular weight isolated | 2010-06-24 |
20100158954 | Brucella Melitensis Mutants and Methods - Certain attenuated mutants of | 2010-06-24 |
20100158955 | Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity - The present invention relates to the preparation and use of variants of the group 5 allergen of the Pooideae which are characterised by reduced IgE reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with T lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies. | 2010-06-24 |
20100158956 | MULTIPLE UNIT DOSAGE FORM HAVING A THERAPEUTIC AGENT IN COMBINATION WITH A NUTRITIONAL SUPPLEMENT - Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described. | 2010-06-24 |
20100158957 | AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF - Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described. | 2010-06-24 |
20100158958 | GASTRIC REFLUX RESISTANT DOSAGE FORMS - Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally. | 2010-06-24 |
20100158959 | Stable Combinations of Amlodipine Besylate and Benazepril Hydrochloride - The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same. | 2010-06-24 |
20100158960 | POROUS POLYMER COATING FOR TOOTH WHITENING - The present invention relates to a tooth-whitening composition comprising (i) a substantially water-insoluble and substantially non-degradable polymer matrix component capable of adhering to the surface of a tooth, provided that if the polymer matrix component is in non-solid form, it is solidifable by chemical alteration; and (ii) gas- or liquid-filled pores embedded in said polymer matrix component, wherein at least a portion of said gas- or liquid-filled pores have at least one size dimension in the range of about 70 nm to about 5 microns, and wherein the gas- or liquid-filled pores and polymer matrix component possess a difference in refractive index of at least 0.1. The invention is also directed to a tooth-whitening system containing the above composition in combination with an applicator device. The invention is also directed to methods for applying the tooth-whitening composition onto teeth. | 2010-06-24 |
20100158961 | STRUCTURED LOTIONS - Provided are structured compositions comprising a quaternary ammonium salt, at least one branched fatty alcohol, and a vehicle. | 2010-06-24 |
20100158962 | CHARGING/SEPARATING COSMETIC MAKEUP COMPOSITIONS FOR KERATIN FIBERS - The present invention relates to a cosmetic composition for making up keratin fibers, comprising a waxy phase containing at least one aqueous dispersion of wax particles, having a plateau Gp modulus of rigidity of greater than or equal to 4,000 Pa and the wax particles of said waxy phase having a size, expressed as the mean “effective” diameter by volume D[4.3], of less than or equal to 1 μm. | 2010-06-24 |
20100158963 | Topical Composition for Influencing Skin Color - Topical compositions for delivering a desirable color are described. The color suitable to be delivered is stable and the result of colorants comprising an antioxidant like lycopene and a second colorant which is a dye or pigment. The topical compositions are stable notwithstanding the fact that they are free of formaldehyde generating preservatives. | 2010-06-24 |
20100158964 | Personal Care Composition Providing Quietness and Softness Enhancement and Articles Using the Same - The present disclosure generally relates to personal care compositions and personal care products. More particularly, the disclosure relates to personal care compositions and personal care products that impart perceivable aesthetic benefits of increased softness, quietness and drapability to the skin or hair of a user. To achieve the perceivable aesthetic benefit, a liquid composition containing water, a skin aesthetic agent selected from fatty acids, fatty alcohols, fatty acid derivatives, fatty alcohol derivatives, and/or combinations thereof, an acidifying agent, and an emulsifying agent may be incorporated into the personal care compositions and personal care products. | 2010-06-24 |
20100158965 | WINDOW STICKER FOR ATTRACTING AND DESTROYING INSECTS - There is disclosed a product for attracting and destroying insects which comprises an active-substance-comprising bait layer (1) together with a bait substance and an insecticide. The active-substance-comprising bait layer (1) furthermore comprises a superdisintegrant whose effect is that, upon the use of the product in an environment with high atmospheric humidity, the active-substance-comprising bait layer (1) does not run. | 2010-06-24 |
20100158966 | SELENIUM-BASED BIOCIDAL FORMULATIONS AND METHODS OF USE THEREOF - Biocidal formulations that include a selenium compound selected from the group consisting of RSeH, RSeR′, RSeSeR, RseSeR′, and RseX, wherein each of R and R′ include an aliphatic or phenolic residue, and wherein X is a protecting group selected from the group consisting of a halogen, an imide, a cyanide, an azide, a phosphate, a sulfate, a nitrate, a carbonate, selenium dioxide, and combinations thereof, are provided. The selenium compounds may be incorporated into an acrylate polymer matrix, or may be incorporated into a molten plastic material. Methods for preventing growth of a species of interest on an object or in a composition are also provided. | 2010-06-24 |
20100158967 | SELENIUM-BASED BIOCIDAL FORMULATIONS AND METHODS OF USE THEREOF - Biocidal formulations that include a selenium compound selected from the group consisting of RSeH, RSeR′, RSeSeR, RseSeR′, and RseX, wherein each of R and R′ include an aliphatic or phenolic residue, and wherein X is a protecting group selected from the group consisting of a halogen, an imide, a cyanide, an azide, a phosphate, a sulfate, a nitrate, a carbonate, selenium dioxide, and combinations thereof, are provided. The selenium compounds may be incorporated into an acrylate polymer matrix, or may be incorporated into a molten plastic material. Methods for preventing growth of a species of interest on an object or in a composition are also provided. | 2010-06-24 |
20100158968 | CELL-PERMEANT PEPTIDE-BASED INHIBITOR OF KINASES - The described invention provides kinase inhibiting compositions containing a therapeutic amount of a therapeutic inhibitor peptide that inhibits at least one kinase enzyme, methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression, and methods for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression using the kinase inhibiting compositions. | 2010-06-24 |
20100158969 | FLEXIBLE IMPLANTABLE COMPOSITES AND IMPLANTS COMPRISING SAME - Described herein are implantable composites, kits comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods. | 2010-06-24 |
20100158970 | IMPLANTABLE COMPOSITES AND IMPLANTS COMPRISING SAME - Described herein are implantable composites, articles comprising the composites, implant devices comprising the composites, and methods of making and using same, including point of use methods. | 2010-06-24 |
20100158971 | METHOD FOR REDUCING THE LIKELIHOOD OF PREECLAMPSIA IN A SUBJECT IN NEED THEREOF - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo. | 2010-06-24 |
20100158972 | METHOD FOR REDUCING THE LIKELIHOOD OF PRETERM LABOR IN A SUBJECT IN NEED THEREOF - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo. | 2010-06-24 |
20100158973 | THERAPEUTIC USES OF CANNABIDIOL COMPOUNDS - The present invention provides the use of a Cannabidiol (CBD) compound for the preparation of a pharmaceutical composition for treatment as well as for the prevention of at least one fundamental parameter affecting a vascular system selected from (a) the cardiovascular system; (b) the peripheral vascular system; or (c) a combination of (a) and (b); as well as pharmaceutical compositions and therapeutic methods for treating the above. A fundamental parameter may include blood/plasma lipid profile; atherosclerosis plaque load; size of heart scar; thickness of heart scar; and cardiac function in general. In accordance with a preferred embodiment the invention concerns treatment of heart scars as well as preventing the formation of heart scars. | 2010-06-24 |
20100158974 | COATED IMPLANT - The present invention relates to an implant or part thereof coated with a wax or a resin. Especially, the present invention relates to an implant or part thereof coated with shellac. | 2010-06-24 |
20100158975 | EXTRACELLULAR MATRIX COMPOSITIONS - The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications. | 2010-06-24 |
20100158976 | COLLAGEN/HYDROXYAPATITE COMPOSITE SCAFFOLD, AND PROCESS FOR THE PRODUCTION THEREOF - A process for producing a collagen/hydroxyapatite (HA) composite scaffold comprises the steps of forming a homogenous suspension of collagen and HA in an acidic solution, lyophilising the suspension until a desired final freezing temperature is reached to produce the composite scaffold, and optionally cross-linking the composite scaffold, wherein the ratio of HA to collagen is at least 1:10 (w/w). Also provided is a collagen/hydroxyapatite (HA) composite scaffold comprising a homogenous distribution of hydroxyapatite within a porous, crosslinked, collagen matrix, wherein the ratio of HA to collagen is at least 1:10 (w/w). Suitably, the composite scaffold has a porosity of at least 99% (v/v), and a compressive stiffness of at least 0.3 KPa. Composite scaffolds of the invention may be used to provide osteoconductive bone implants and tissue engineering implants. | 2010-06-24 |
20100158977 | PROGENITOR CELLS FROM URINE AND METHODS FOR USING THE SAME - Provided herein are urine progenitor cells and methods for producing a culture of urine progenitor cells from a urine sample. The cells may be selected based upon the use of a selective cell medium, based upon morphology, and/or by selecting cell-specific markers. Also provided is an isolated urine progenitor cell that is c-kit positive and can differentiate into urothelium, smooth muscle, endothelium or interstitial cells. Methods of use of urine progenitor cells are provided, wherein cell are seeded onto a tissue scaffold are provided. Methods of treating a subject in need thereof are also provided, including providing a bladder tissue substrate that includes differentiated UPCs and transplanting the substrate into the patient. Finally, kits are provided that include a container suitable for the transport of a urine sample; media; one or more antibiotics; a package for holding said container, media, and antibiotics; and optionally, instructions for use. | 2010-06-24 |
20100158978 | BIOACTIVE SPRAY COATING COMPOSITIONS AND METHODS OF MAKING AND USES THEREOF - Described herein are spray coating compositions, implant devices comprising the compositions, and methods of making and using same, including point of use methods. | 2010-06-24 |
20100158979 | TEMPORAL RELEASE OF GROWTH FACTORS FROM 3D MICRO ROD SCAFFOLDS FOR TISSUE REGENERATION - The present invention relates to the use of three-dimensional microrod scaffolds for the temporal release of growth factors useful in tissue regeneration, engineering and treatment of disorders. | 2010-06-24 |
20100158980 | DRUG DELIVERY DEVICES FOR DELIVERY OF THERAPEUTIC AGENTS - Drug delivery devices comprising a non-bioabsorbable polymer structure and a composition comprising an active agent have been discovered. The drug delivery devices may be used to treat ocular conditions, among other diseases and conditions. In addition, a method of treating an ocular condition has been discovered comprising implanting a drug delivery device which releases the active agent at a rate of | 2010-06-24 |
20100158981 | Block Biodegradable Copolymers for Medical Devices - Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes. | 2010-06-24 |
20100158982 | SHEET FOR GUIDING REGENERATION OF MESENCHYMAL TISSUE AND PRODUCTION METHOD THEREOF - To provide a sheet for guiding regeneration of mesenchymal tissue having improved formability, strength, absorbability and efficiency, the sheet is produced by steps of containing a culture medium in a surface of a porous sheet produced by freezing a bioabsorbable polymer material dissolved with an organic solvent and drying it, seeding a mesenchymal cell grown after taking from biotissue, and differentiating the mesenchymal cell to a mesenchymal tissue precursor cell, where the mesenchymal tissue precursor cell and an extracellular substrate are adhered on the surface of the porous sheet containing a culture medium, and the extracellular substrate is secreted in a process of the mesenchymal cell being differentiated to the mesenchymal tissue precursor cell. | 2010-06-24 |
20100158983 | METHOD FOR INCREASING THE PERMEABILITY OF POLYMER FILM - Polymer membranes are disclosed having increased permeability. The process of the present disclosure, for instance, can increase the ion permeability of membranes and/or the gas permeability of membranes. In one embodiment, for instance, a precursor polymer is subjected to energy in an amount sufficient to form damage tracks through the thickness of the polymer. The damage tracks are then oxidized to form free radical groups. The precursor polymer is then hydrolyzed causing ion groups to form that cluster along the damage tracks. In one embodiment, sulfonated tetrafluoroethylene-based copolymer ionomer membranes are formed that have increased conductivity. Other ionomer membranes that may be formed according to the present disclosure include copolymers of a vinyl hydrocarbon and a vinyl carboxylic acid. | 2010-06-24 |
20100158984 | Encapsulates - An encapsulate comprises an outer shell and an inner core, the inner core comprising an ingredient selected from plant sterol compounds such as phytosterols and/or phytostanols and/or their esters, and at least one, preferably at least two, of the following groups: a, b, c, d, e, f, g, h, i, j, k.
| 2010-06-24 |
20100158985 | Porous structures of microbial-derived cellulose for in vivo implantation - This invention relates to polysaccharide materials and more particularly to microbial-derived cellulose having the porosity and containing pores of the desired size making it suitable for cellular infiltration during implantation and other desirable properties for medical and surgical applications. The invention also relates to the use of porous microbial-derived cellulose as tissue engineering matrices, human tissue substitutes, and reinforcing scaffolds for regenerating injured tissues and augmenting surgical procedures. The invention outlines various methods during and after fermentation to create porous microbial cellulose capable of allowing cell infiltration while preserving the physical properties of the microbial-cellulose. | 2010-06-24 |
20100158986 | Personal Care Composition Providing Quietness and Softness Enhancement, Methods of Preparing and Articles Using the Same - The present disclosure generally relates to personal care compositions and personal care products. More particularly, the disclosure relates to personal care compositions and personal care products that impart perceivable aesthetic benefits of increased softness, quietness and drapability to the skin or hair of a user. To achieve the perceivable aesthetic benefit, a protonated skin aesthetic agent selected from fatty acids, fatty alcohols, fatty acid derivatives, fatty alcohol derivatives, and/or combinations thereof, may be incorporated into the personal care compositions and personal care products. To produce the liquid composition, a deprotonated skin aesthetic agent is first provided. The deprotonated skin aesthetic agent is added to an aqueous liquid solution. The aqueous liquid solution is then acidified with an acidifying agent to protonate the deprotonated skin aesthetic agent. Finally, the aqueous liquid solution is incorporated onto a wipe substrate. | 2010-06-24 |
20100158987 | Adhesive Label With Bittering Agent and Fluidifying Agents for Natural Airway Secretions - Label for the outerwear for thinning of airway secretions, containing a bittering agent to reduce the likelihood of accidental ingestion. | 2010-06-24 |
20100158988 | CEREAL BETA GLUCAN COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF - Cereal β(1-3) β(1-4) glucan is used as a film or coating agent to produce clear, edible, biodegradable, delivery, lubricating, and protecting agents. Cereal β(1-3) β(1-4) glucans are distinctive polymers of glucose differentiated from other polymers by not only their source but also their physicochemical properties. The β(1-3) β(1-4) forms a matrix to sequester other materials, such as pharmaceutical, medical and therapeutic agents, flavours, fragrances. The technology has applications to essential oils and non-aqueous materials that are rendered deliverable by the β(1-3) β(1-4) glucan. The β(1-3) β(1-4) glucan films described may be consumed whereby they dissolve in the mouth in a controlled manner and may be used for the delivery of pharmaceutical, medical or confectionery products. | 2010-06-24 |
20100158989 | Hemostatic Agent Composition, Delivery System and Method - A hemostatic agent composition, delivery system and method include a hemostatic agent composition which is inert and non-reactive relative to blood clotting proteins and platelets. The composition includes a clay material combined with a humectant in a stable suspension embedded in a mesh fabric and, when dried, is capable of accelerating the formation of a stable clot when applied to an actively bleeding wound or drying other bodily fluids. | 2010-06-24 |
20100158990 | TRANSDERMAL METHOD AND PATCH FOR CORTICOSTEROID ADMINISTRATION - A method of treating an individual having a disease or for diagnostic purposes requiring administration of a corticosteroid, which involves applying to a portion of intact derma on the individual a transdermal patch having a backing layer and a matrix adhesive layer. The matrix adhesive layer includes a skin-compatible pressure-sensitive adhesive, a corticosteroid, and at least one permeation enhancer. The matrix adhesive layer, when applied to the skin of the individual, transdermally and continuously delivers the corticosteroid to the mammal for systemic treatment of the disease or for the diagnostic purpose. | 2010-06-24 |
20100158991 | PATCH PACKAGE STRUCTURE - A patch package structure which includes: a package including a first sheet material which is planar and a second sheet material which has been molded, a peripheral area of the first sheet material having been sealed to a peripheral area of the second sheet material to constitute the package, and a patch disposed in the package; in which the patch includes a backing, a pressure-sensitive adhesive layer formed on at least one side of the backing, and a release liner which protects the pressure-sensitive adhesive surface of the pressure-sensitive adhesive layer, the release liner having a weakening line for assisting a removal of the release liner; and in which the second sheet material has specific first protrudent part, second protrudent part, third protrudent part and elevated part in a central area thereof except the peripheral area thereof. | 2010-06-24 |
20100158992 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS - There is disclosed a method for treating or preventing fungal infections comprising the administration of at least one glucan synthase inhibitor of a formula as described above in the specification or a pharmaceutically acceptable salt thereof; also claimed are methods of preparing pharmaceutical compositions comprising a compound as described above in the specification and a carrier, method of treating or preventing fungal infections comprising administration of combinations of glucan synthase inhibitor of a formula as described above in the specification and other antifungal agents, and method of treating or preventing fungal infections comprising administration of pharmaceutical compositions prepared according to a method described above in the specification, and a method of preparing a kit in a single package of the above described pharmaceutical composition and other antifungal agents. | 2010-06-24 |
20100158993 | Topical Gel Compositions - Topical alcoholic gel compositions are disclosed that are useful for delivering therapeutic levels of an NSAID to target in and below the skin. The compositions comprise a topically active drug, an alcoholic solvent, a polymeric thickener, and optionally a keratolytic agent. In one embodiment, excellent viscosity for dermal application is attained without the need of a step for neutralizing the pH of the composition. Alcoholic and alcohol-free topical compositions comprising an NSAID prodrug are also disclosed. The compositions are particularly useful for the treatment of pseudofolliculitis barbae. | 2010-06-24 |